At present, China's medical insurance reimbursement drug list mainly includes three parts: western medicine, Chinese patent medicine and Chinese herbal pieces. Among them, western medicines 1 133 and 1 137, 927 Chinese patent medicines and 47 ethnic medicines are allowed to be paid by basic medical insurance and industrial injury insurance funds respectively. There are 127 kinds and 1 categories of Chinese herbal pieces that are not paid by medical insurance and industrial injury insurance funds. Among them, 99 kinds of unilateral refusal, 28 kinds of single and multiple refusal, 1.

A new batch of drugs for reimbursement include Gleevec, Libitai, Iressa, Rebodo, Ebitur, Qingweike, ATG- Fei Sen News (anti-human T-cell rabbit immunoglobulin), Herceptin, Norwich, Rituximab, Foslino (lanthanum carbonate), Tyson, Somadulin, and Fuxo. These drugs are mainly used to treat major diseases such as gastric cancer and breast cancer. These drugs are expensive and there are no substitutes. Therefore, the addition of these drugs to the medical insurance reimbursement list has also reduced a lot of burden for cancer patients.

Second, what are the medical insurance reimbursement methods?

1, "Class A List" drugs are necessary for clinical treatment, with wide application and good curative effect, and the price is lower among similar drugs. The drugs listed in Category A are reimbursed at the rate of 100% and paid by the basic medical insurance fund;

2. The drugs in the "Category B Drug List" are available for clinical use with good curative effect, and the price of similar drugs is slightly higher than that in the "Category A Drug List". Part of the drug expenses of "Class B Catalogue" shall be paid by the insured, and part of the expenses shall be reimbursed. After the insured pays a certain percentage of the expenses, it will be paid according to the basic medical insurance.

3. Class C is an unnecessary and expensive drug except the above two categories. Class C drugs are completely at their own expense.